強気
$2.26
シナリオ価格
$0.564
+0.036 (+6.36%)終値時点
China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market.
China Pharma Holdings Inc is not a good buy right now. The current price is $0.56, which is significantly down from its 52-week high of $19.19, indicating a loss of over 97% from its peak. The RSI is at 35.803, suggesting the stock is oversold, but the overall trend is negative with a year-to-date change of -53.41%. The company has reported consistent net losses, with a net income of -1,458,123 USD in Q2 2026 and a gross margin of only 8.81%. The main risk is its declining revenue and negative earnings, which could further impact its stock price.
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

China Pharma Holdings Prices Direct Offering of 2.5 Million Shares

Biotech Stocks Reach 52-Week Highs Amid Clinical Trial Progress

China Pharma Responds to Unusual Trading Activity

Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

What Is a 1‑for‑10 Reverse Stock Split?
China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
China Pharma Holdings Inc is not a good buy right now. The current price is $0.56, which is significantly down from its 52-week high of $19.19, indicating a loss of over 97% from its peak. The RSI is at 35.803, suggesting the stock is oversold, but the overall trend is negative with a year-to-date change of -53.41%. The company has reported consistent net losses, with a net income of -1,458,123 USD in Q2 2026 and a gross margin of only 8.81%. The main risk is its declining revenue and negative earnings, which could further impact its stock price.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。